Think success at full scale right from the start

Discover 6 tips for early-stage MDx companies seeking successful commercialisation.

READ THE ARTICLE

"It's like you are an extension of our family."

- Aimee Franko
Scientist, DiaSorin

on their relationship with
LGC, Biosearch Technologies

Many of the choices you make during the R&D phase can have a substantial impact on how successful you are in taking your molecular diagnostic assay to market. That’s why choosing the right supplier for your assay components is crucial in turning your big ideas into large-scale reality.

With long-term experience, proven quality components, and flexible manufacturing, LGC, Biosearch Technologies’ broad portfolio of critical components for PCR and NGS based MDx applications and solutions help ensure that you are preparing for commercialisation right from the outset.

Long-term experience empowers us to anticipate your needs early on

Your supplier’s knowledge level and responsiveness are crucial in solving difficult R&D problems and proactively anticipating problems and challenges that may surface during scale up.

With 35 years of experience, we know that a true partnership is the only way to understand your current and future needs. LGC, Biosearch Technologies’ scientists are hands-on from the time of assay inception, positioning us to see potential challenges and adjust your design strategy to facilitate a seamless transition to scale up and avoid costly troubleshooting during production.

Quality components for repeatable and consistent performance

Component quality and consistency are vital throughout product design, manufacturing, regulatory approval and commercialisation. From avoiding uncertainty during early R&D to ensuring compliance with relevant ISO or other regulatory requirements, companies need to be confident that their overall product quality is supported by quality components.

LGC, Biosearch Technologies’ vertical product integration ensures comprehensive traceability for repeatable (lot-to-lot) and consistent (within lot) production, enabling robust, high-quality assays that support rapid regulatory approval and confident reliance on assay supply and performance.

Flexible manufacturing enables us
to fine-tune to your needs

If your supplier uses a “fixed” manufacturing platform, its ability to adjust for fluctuating variables such as yield, purity and performance when moving from small pilot to full-scale production batches will be limited. Moreover, accommodating your specific needs that lie beyond the fixed manufacturing platform might be a significant challenge.

The experience and flexibility of LGC, Biosearch Technologies’ production platform enables our chemists to fine-tune your design strategy at crucial steps during production, empowering us to reliably deliver the same consistent product regardless of scale, ensuring your needs are met.

Broad portfolio and customisation capabilities for confidence from R&D through commercialisation

Molecular diagnostics companies in the R&D phase will often look at initial cost as a key driver for component choice without considering the long-term implications of their decisions. However, examining the breadth and capabilities of a supplier’s portfolio is a key consideration in preparing for scale up and for successful long-term commercialisation.

LGC, Biosearch Technologies’ broad portfolio of quality, customisable assay components, along with our responsive manufacturing capabilities, rapid order turn-around, and on-time delivery, will help speed your product development and ensure confidence from start to finish.

Find out more about LGC, Biosearch Technologies
and our portfolio of quality assay components.

EXPLORE OUR PORTFOLIO

 “6 Tips for Early-Stage MDx Companies Seeking Successful Commercialisation”

 

Learn how experts evaluate suppliers and assay components by downloading this informative article. Harry Glorikian – a general partner at New Ventures Funds and a veteran board member and storied investor in MDx companies – discusses how to establish a macro plan for reaching diagnostic success based on real world insights with Sébastien Chapdelaine, Senior Director of R&D at Meridian Bioscience, Inc.